Philippe Halfon

Philippe Halfon is the head of internal medicine and infectious disease at the European Hospital of Marseille (Hôpital européen de Marseille).[1] He is a specialist in viral diseases, especially on Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV).

Philippe Halfon
Born
Tunis
NationalityFrench
EducationMD, PharmD, PhD
Alma materIHU Mediterranean Infection Doctoral School of Sciences of life
Occupation(s)Physician and infectious disease researcher.
Employer(s)Head of Internal Medicine and Infectious Diseases section, European Hospital

Medical education

Halfon received a PharmD from the University of Pharmacy of Aix-Marseille University in 1984, and certificates of higher studies in hematology (1985), immunology (1986), bacteriology-virology (1985), parasitology (1987), cellular biology (1990), molecular biology (1991) and AIDS (1992).[2]

He received his PhD from the University of Luminy, Aix-Marseille University (1996-1999), and his MD from the University of Medicine of Marseille (1998-2006).

During 1984-1987 Halfon was a resident in microbiology at the Medical Centre of the University Hospital of Marseilles. After that, he was a Junior Resident in Biology for two years in Médaille d’or des Hôpitaux. He was a senior Resident in Virology between 1987 and 1988 at the Medical Center of the University Hospital of Marseilles.[3] This was followed by fellowships in Clinical Microbiology and Biochemistry between 1989 and 1995, and then a fellow in Clinical Infectious Diseases and Internal Medicine at the University Hospital of Marseille (2003- 2007) and Senior Resident in Infectious Diseases In Montreal, Canada (2001).[3]

Career

He was appointed Research Director (HDR) at the University of Medicine of Marseille (2003). Halfon was an Infectious Diseases Specialist (2009), obtained an Oncology and Genetic certification (2015), and became associate professor of internal medicine at Paris Hospital College.

He has also been a visiting professor of medicine at Emory University, Atlanta, Georgia, (2008), and visiting professor of medicine, Hadassah, Jerusalem; Israel (2009).[4][5][6]

Halfon is also the co-founder of Alphabio Clinical Laboratories, and co-founder and CEO of Genoscience Pharma.[7][8] [9]

Research

Halfon's research deals with cancer[10] and virology. On these topics, he has written 250 peer-reviewed articles.[11]

In addition, he has developed[12][13] a potential new drug against Sars-CoV-2,[14] GNS561, with in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition.[15]

Companies

Halfon is the president and founder of Alphabio, a clinical network of clinical laboratory in Marseille.[16] Its main product is iBiote,[17] a microbiota analysis service.[18][19]

He founded Genoscience Pharma in 2001. The company was initially focused on the development of anti-HCV agents. Two protease inhibitors were thus developed and out-licensed to BioLineRx: BL-8020, an orally administered treatment for Hepatitis C, and BL-8030, a second-generation NS3 protease inhibitor for oral treatment of Hepatitis C,[20]

Halfon is also co-founder, together with Noam Danenberg, of Panmed Inc.,[3] a biomedical investment firm which was one of the owners of BL8020, an add-on drug to treat HCV non-responders.

References
  1. "Pôle hématologie, infectiologie et médecine interne". L’hôpital Européen. 22 October 2013. Retrieved 18 November 2020.
  2. "Dr. Philippe HALFON" (PDF). IMéRA, Maison des astronomes, Marseille. Retrieved 18 November 2020.
  3. "LO2A drops outperforms Systane on some measures treating DES patients suffering from Primary Sjogren". 1NewsReport. 23 November 2020.
  4. "Visiting Profesor Hebrew University".
  5. "HIV carriers can now have healthy children thanks to innovative treatment at Hadassah medical center". Hadassah University Medical Center. Retrieved 17 November 2020.
  6. "Burden and prevention of Viral Hepatitis in Israel: Lessons learnt and the way forward" (PDF). Viral Hepatitis Prevention Board. Retrieved 17 November 2020.
  7. "Most Innovative European Biotech SME for 2018". Genoscience Pharma. Retrieved 18 November 2020.
  8. "La réponse de Philippe Halfon, MD, PharmD, PhD, Chef de Pole de Médecine Interne et Maladies Infectieuses à l'Hôpital Européen, directeur du laboratoire Alphabio, Marseille Groupe Expert de Médecins de l'AMIF (GEMAMIF)". Association des Médecins Israélites de France. 23 March 2020. Retrieved 18 November 2020.
  9. "Philippe Halfon, Md, Phd, Pharmd CEO And Founder Genoscience Pharma". lyfebulb. Retrieved 18 November 2020.
  10. "Genoscience Pharma Announces Extension of GNS561 Phase 1/2 Clinical Trial to Patients with Pancreas or Colorectal Cancer with Liver Metastasis". Genoscience Pharma. Retrieved 18 November 2020.
  11. "Philippe Halfon articles". PubMed. Retrieved 18 November 2020.
  12. "COVID-19, GNS561's Assault begins in France !". Retrieved 18 November 2020.
  13. "Coronavirus : une étude sur 100 patients marseillais pour "décrypter le dérèglement immunitaire"". La Provence. 16 April 2020. Retrieved 18 November 2020.
  14. "COVID 2019 : identité, prévention et traitement". Alliance Solidaire. 20 April 2020. Retrieved 18 November 2020.
  15. Halfon, P.; Bestion, E.; Zandi, K.; Andreani, J.; Baudoin, J. P.; La Scola, B.; Mege, J. L.; Mezouar, S.; Schinazi, R. F. (2020). "GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition". bioRxiv 10.1101/2020.10.06.327635.PMID 33052342PMC 7553169
  16. Allies Biopharma
  17. ibiote
  18. "Alphabio annonce le lancement d'un nouveau test pour l'analyse du microbiote intestinal, iBioteTM". 20 December 2019. Retrieved 18 November 2020.
  19. ""La situation marseillaise va se débloquer très vite" dixit O. Véran". La Provence. 31 August 2020. Retrieved 18 November 2020.
  20. "BioLineRx signs pact with Genoscience & RFS Pharma to develop and commercialize BL-8030 to treat hepatitis C". Pharmabiz.com. Jerusalem, Israel. 8 February 2012. Archived from the original on 21 February 2015. Retrieved 8 February 2012.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.